Back

Select your region

Arrange a consultation about stem cells

Learn more

News

News

News from the field of stem cells from the umbilical cord

Search:

Umbilical cord blood saves girl with severe pulmonary hypertension

Umbilical cord blood saves girl with severe pulmonary hypertension

Stem cells derived from umbilical cord blood are used as standard treatment for 80 diseases. In recent years, there have been new reports about the use of these cells for additional diseases. Doctors in Germany successfully used them to treat pulmonary hypertension in a 3-year-old girl. Pulmonary hypertension - what is it? Pulmonary arterial hypertension (PAH) is currently an incurable disease. It leads to death within about five to seven years after diagnosis. The disease is named for the increased pressure in the pulmonary vessels and can lead to overload and failure of the right side of the heart. The causes of pulmonary hypertension can vary, but all patients struggle with shortness of breath or severely limited mobility, among other symptoms. For this reason, researchers are constantly looking for new ways and therapies to extend the lives of people with pulmonary hypertension and improve their comfort.       Stem cells and pulmonary hypertension Doctors in Germany have announced the first success in treating pulmonary hypertension with cells from umbilical cord blood (HUCMSC - human umbilical cord mesenchymal stem cell). The patient was a three-year-old girl suffering from PAH and Rendu-Osler-Weber disease who was intravenously injected with allogeneic stem cells from her baby brother's umbilical cord blood. The injections were performed five times over a six-month period. The girl's clinical condition was assessed after two and six months. Not only were there no side effects, but there was also an increase in exercise tolerance and an improvement in cardiovascular parameters. Before the stem cell infusion, the girl suffered from growth disorders and weight gain. After the first infusion she started to grow - in three months she grew 10 cm. Moreover, the girl is now six years old and feels well. According to the researchers, the regeneration of the vascular system damaged by the disease, as well as the significant alleviation of cellular damage, are responsible for the improvement due to cord blood stem cell therapy. The study reports, among other things, the role of the prostaglandin PGE2, which may play a key role in the regenerative and immunomodulatory abilities of cord blood stem cells. The researchers unanimously emphasize that further research should be conducted and that additional opportunities and uses for cord blood-derived stem cells should be actively sought. Bibliography:  https://www.aabb.org/news-resources/news/article/2022/07/13/cord-blood-derived-stem-cells-may-help-treat-pulmonary-hypertension https://www.sciencedirect.com/science/article/abs/pii/S1053249822018472 https://www.nature.com/articles/s44161-022-00083-z
Read more
Vermehrung von Nabelschnurblut-Stammzellen als neue Hoffnung für Krebspatienten

Vermehrung von Nabelschnurblut-Stammzellen als neue Hoffnung für Krebspatienten

Umbilical cord blood stem cells have been used in medicine for over 30 years to treat more than 80 different diseases such as leukemias, lymphomas and sickle cell anemia. In the field of regenerative medicine, the use of umbilical cord blood stem cells has also been shown to provide clinical benefits to patients. Because of its limitations, cord blood has been used more frequently in pediatric patients than in adults. However, the results of recent clinical trials show that the increased cord blood stem cells can also be successfully transplanted in adult patients. Umbilical cord blood stem cells are the hope of 21st century medicine. Currently, more than 3,000 studies are underway worldwide in various fields to explore the potential of stem cells. The results of a study on the use of augmented cord blood stem cells in the treatment of patients with blood cancers, published last week, show that cord blood stem cells grown in the laboratory and transplanted into patients are of significant clinical benefit. Omidubicel is the name of a preparation of hematopoietic cells from one unit of umbilical cord blood that have been propagated under laboratory conditions. A clinical trial evaluated its effectiveness compared with standard cord blood stem cell transplantation. The study lasted from January 2015 to January 2020 and included 125 patients aged 13 to 65 with blood cancers. Patients who received omidubicel achieved adequate white blood cell recovery 10 days earlier than patients who underwent standard therapy. They also had faster platelet recovery [up to 42 days vs. 90 days], a lower incidence of bacterial or invasive fungal infections (37% vs. 57%), and spent more time out of the hospital in the first 100 days after transplantation than patients in the control group. The proliferation of hematopoietic cells was the Holy Grail of hematology - an idea that, despite many attempts over decades, no one was able to realize. The results of this study show that the point has been reached where the number of cells no longer matters. Even more - the increased cells from cord blood can regenerate the hematopoietic system faster after transplantation. This could mean a wider introduction of this type of methods into clinical practice - says Emilian Snarski, MD, Medical Director of FamiCord Group. This is another study that shows the possibility of propagation of hematopoietic cells from cord blood and their effective use in the treatment of blood cancers. Thanks to such methods of proliferation of hematopoietic cells from cord blood, cord blood can be effectively used even if the number of collected cells was relatively small. Link to the abstract
Read more